Trial Information
A Single-arm, Open-label, Multicenter Feasibility Trial of Bevacizumab Given in Combination With Concomitant Chemoradiation (Cisplatin and Vinorelbine) in Locally Advanced Unresectable Non-squamous, Non-small Cell Lung Cancer
Inclusion Criteria:
- patients >=18 years with locoregional advanced unresectable non-squamous NSCLC;
- ECOG performance status of 0 or 1;
- no prior thoracic head and neck irradiation or surgical resection for current lung
cancer.
Exclusion Criteria:
- mixed, non-small cell and small cell tumors;
- mixed adeno-squamous carcinomas with a predominant squamous component;
- evidence of tumor invasion or encasement of major vessels;
- history of grade >=2 hemoptysis;
- presence of cavitations in lung lesions at baseline.
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Safety: Adverse events; clinical laboratory parameters; physical exam including vital signs; performance status.
Outcome Time Frame:
Throughout study
Safety Issue:
No
Principal Investigator
Clinical Trials
Investigator Role:
Study Director
Investigator Affiliation:
Hoffmann-La Roche
Authority:
Canada: Health Canada
Study ID:
BO21247
NCT ID:
NCT00773188
Start Date:
December 2008
Completion Date:
October 2010
Related Keywords:
- Non-Small Cell Lung Cancer
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms